NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Polaryx Therapeutics PLYX

Polaryx Therapeutics listed on Nasdaq on 2 Feb 2026 and is not in the S&P 500. It is worth $75.3 million. Its price history starts on 13 Feb 2026. Its board has 5 directors, 3 of them independent. 1 other officer is on file.

Chair and CEO
Alex Keun Mo Yang
Listed
2 Feb 2026 on Nasdaq, IPO filings and terms
Headquarters
Paramus, NJ
Market cap
$75M
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Polaryx Therapeutics' market cap since February 2026

Weekly, up to 13 Nov 2026

Mar 2026AprMayJunJulAugSepOctNov$90M

Board and leadership

Board and officers

Board from the proxy filed 28 Jul 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (5)
Alex Keun Mo YangChair; Chief Executive OfficerNot independent 路 since 2021Chair; Chief Executive Officer2021No57
Mitchel BergerDirectorIndependent 路 since 2026 路 Audit, Compensation (chair), GovernanceDirector of the Brain Tumor Center, University of California, San FranciscoDirector2026YesAudit, Compensation (chair), Governance73
Francis A. Braun IIIDirectorIndependent 路 since 2026 路 Audit (chair)Senior Advisor, Stout Risius Ross, LLCOther boards: SHF HoldingsDirector2026YesAudit (chair)65
G. Michael LandisChief Financial OfficerNot independent 路 since 2025Chief Financial Officer2025No60
Charles S. RyanLead Independent DirectorIndependent 路 since 2026 路 Audit, Compensation, Governance (chair)President, Quince Therapeutics, Inc.Other boards: Quince TherapeuticsLead Independent Director2026YesAudit, Compensation, Governance (chair)62
Officers (1)
O. Andrew JohnChief Investment OfficerLast filed 29 Jan 2026Chief Investment Officer

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $368,003 in 2 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
27 May 2026BuyAlex Keun Mo YangChief Executive OfficerChief Executive OfficerBuy88,453$360K
18 Feb 2026BuyG. Michael LandisChief Financial OfficerChief Financial OfficerBuy2,867$8K

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 departure and 0 appointments of directors and officers in the last two years.

Left the company or board 1Appointed 0WARN layoff notices 0Large insider sales 0Jan 2025AprJulOctJan 2026AprJulOct

Events, newest first

Not on file: no 13F holdings reported, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.